Navigation Links
ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development
Date:7/28/2014

LOS ANGELES, SINGAPORE, and TOKYO, July 28, 2014 /PRNewswire/ -- ImaginAb, Inc. today announced today announced that it has appointed Roger Crystal, MD as Vice President of Business Development. Dr. Crystal most recently served in the Global Business Development Product Acquisition & Licensing team at G.E. Life Sciences.

"Roger's experience in developing business strategy and partnerships in the precision medicine space will be extremely valuable as we continue to partner with biotechnology and pharmaceutical companies across the spectrum to extend the reach of ImaginAb's capabilities," said Dr. Christian Behrenbruch, co-founder and CEO of ImaginAb. "We are very pleased to welcome Roger to Los Angeles and look forward to his contributions as a member of the ImaginAb executive team."

Prior to joining ImaginAb, Dr. Crystal served on the Global Business Development Product Acquisition & Licensing team at G.E. Life Sciences where he was responsible for evaluating in vivo and in vitro molecular and IT technologies for acquisitions, licensing or partnering deals.  In this capacity he also managed pharmaceutical company engagements, out-licensing deals and commercialization partnerships for late stage molecular imaging agents including molecular imaging technologies. Dr. Crystal also has prior management consulting and corporate M&A experience from AT Kearney and Goldman Sachs.

"ImaginAb's proprietary antibody fragment technology has the potential to transform the way patients are staged and managed in cancer and immunology indications," commented Dr. Crystal. "I am enthusiastic to be joining ImaginAb, particularly at a time when the application of our products has the potential to further advance the tremendous progress being made in the immuno-oncology field."

Dr. Crystal holds degrees in Medicine and Physiology from the University of Birmingham and an MBA from the London Business School.  Dr. Crystal began his career as a surgeon at University College Hospital London and is a member of the Royal College of Surgeons of England specializing in otolaryngology, most recently at St Mary's Hospital (Imperial College), London.

About ImaginAb
ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging.  The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare.

For more information, visit www.imaginab.com.


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer
2. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
3. ImaginAb and Singapore Radiopharmaceuticals Sign Master Service Agreement
4. Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer
5. Pharmavite Appoints Timothy Toll Chief Customer Officer
6. Silk Road Medical Appoints Ground Breaking Innovator as Chief Technology Officer
7. BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors
8. PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board
9. Nonin Medical Appoints Ash Keswani Vice President of Marketing
10. InspireMD Appoints Dr. James Barry as Chief Operating Officer
11. Xencor Appoints Kurt Gustafson to Board of Directors; Promotes John Desjarlais to Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/22/2017)...  As the latest Obamacare repeal effort moves is ... (R-LA) and Lindsey Graham (R-SC) medical device ... industry is in an odd place.  The industry wants ... tax on medical device sales passed along with the ... increased visits and hospital customers with the funding to ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
Breaking Medicine News(10 mins):